Pittsburgh, PA – According to filings with the U.S. Securities and Exchange Commission, Cernostics is raising $12,476,960.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Michael Hoerres played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Cernostics
Cernostics is a diagnostics company focused on delivering next generation cancer diagnostics and prognostics through a unique approach to tissue analysis. Most current diagnostic approaches offer a limited view of cancer because they fail to evaluate the tumor as a system composed of multiple interacting cell types. Cernostics takes a tissue systems biology approach to anatomic pathology. Its patent-protected technology platform, TissueCypher, uniquely analyzes whole slide digital images with multiplexed fluorescence, providing greater information and accuracy than traditional subjective tissue diagnostics. Learn more about our technology platform [www.cernostics.com] and how it will change the future of cancer diagnostics.

To learn more about Cernostics, visit http://www.cernostics.com/

Contact:
Michael Hoerres, Chief Executive Officer
412-481-5690
mhoerres@cernostics.com
https://www.linkedin.com/in/mike-hoerres-aa72671/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved